Logo image of SCYX

SCYNEXIS INC (SCYX) Stock Fundamental Analysis

NASDAQ:SCYX - Nasdaq - US8112922005 - Common Stock - Currency: USD

0.9677  +0.01 (+0.8%)

Fundamental Rating

2

SCYX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SCYX have multiple concerns. SCYX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SCYX had negative earnings in the past year.
SCYX had a negative operating cash flow in the past year.
In the past 5 years SCYX reported 4 times negative net income.
SCYX had negative operating cash flow in 4 of the past 5 years.
SCYX Yearly Net Income VS EBIT VS OCF VS FCFSCYX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

1.2 Ratios

The Return On Assets of SCYX (-36.79%) is comparable to the rest of the industry.
The Return On Equity of SCYX (-62.26%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -36.79%
ROE -62.26%
ROIC N/A
ROA(3y)-15.59%
ROA(5y)-38.9%
ROE(3y)-650.17%
ROE(5y)-521.79%
ROIC(3y)N/A
ROIC(5y)N/A
SCYX Yearly ROA, ROE, ROICSCYX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

1.3 Margins

SCYX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SCYX Yearly Profit, Operating, Gross MarginsSCYX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K -40K

More info and screens

3

2. Health

2.1 Basic Checks

SCYX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SCYX has more shares outstanding
The number of shares outstanding for SCYX has been increased compared to 5 years ago.
The debt/assets ratio for SCYX has been reduced compared to a year ago.
SCYX Yearly Shares OutstandingSCYX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
SCYX Yearly Total Debt VS Total AssetsSCYX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

SCYX has an Altman-Z score of -5.70. This is a bad value and indicates that SCYX is not financially healthy and even has some risk of bankruptcy.
SCYX has a Altman-Z score of -5.70. This is in the lower half of the industry: SCYX underperforms 65.63% of its industry peers.
A Debt/Equity ratio of 0.23 indicates that SCYX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.23, SCYX perfoms like the industry average, outperforming 43.23% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z -5.7
ROIC/WACCN/A
WACC11.22%
SCYX Yearly LT Debt VS Equity VS FCFSCYX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

SCYX has a Current Ratio of 3.13. This indicates that SCYX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.13, SCYX is in line with its industry, outperforming 51.56% of the companies in the same industry.
A Quick Ratio of 3.13 indicates that SCYX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.13, SCYX is in line with its industry, outperforming 55.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 3.13
SCYX Yearly Current Assets VS Current LiabilitesSCYX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

2

3. Growth

3.1 Past

The earnings per share for SCYX have decreased strongly by -155.22% in the last year.
The Revenue for SCYX has decreased by -93.70% in the past year. This is quite bad
SCYX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 251.82% yearly.
EPS 1Y (TTM)-155.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)-93.7%
Revenue growth 3YN/A
Revenue growth 5Y251.82%
Sales Q2Q%-62.52%

3.2 Future

SCYX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -34.73% yearly.
Based on estimates for the next years, SCYX will show a very negative growth in Revenue. The Revenue will decrease by -16.26% on average per year.
EPS Next Y-143.66%
EPS Next 2Y-46.26%
EPS Next 3Y-11.24%
EPS Next 5Y-34.73%
Revenue Next Year-90.43%
Revenue Next 2Y-33.28%
Revenue Next 3Y-2%
Revenue Next 5Y-16.26%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SCYX Yearly Revenue VS EstimatesSCYX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 50M 100M
SCYX Yearly EPS VS EstimatesSCYX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SCYX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SCYX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SCYX Price Earnings VS Forward Price EarningsSCYX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SCYX Per share dataSCYX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A cheap valuation may be justified as SCYX's earnings are expected to decrease with -11.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-46.26%
EPS Next 3Y-11.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SCYX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCYNEXIS INC

NASDAQ:SCYX (3/7/2025, 8:00:02 PM)

0.9677

+0.01 (+0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-26 2025-03-26/amc
Inst Owners32.1%
Inst Owner Change-8.24%
Ins Owners2.4%
Ins Owner Change10.66%
Market Cap36.72M
Analysts84.44
Price Target6.8 (602.7%)
Short Float %2.27%
Short Ratio3.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.55%
Min EPS beat(2)-45.6%
Max EPS beat(2)20.51%
EPS beat(4)2
Avg EPS beat(4)-2.83%
Min EPS beat(4)-91.18%
Max EPS beat(4)104.96%
EPS beat(8)5
Avg EPS beat(8)-1.9%
EPS beat(12)7
Avg EPS beat(12)4.62%
EPS beat(16)10
Avg EPS beat(16)0.64%
Revenue beat(2)1
Avg Revenue beat(2)37.78%
Min Revenue beat(2)-89.53%
Max Revenue beat(2)165.09%
Revenue beat(4)3
Avg Revenue beat(4)183.69%
Min Revenue beat(4)-89.53%
Max Revenue beat(4)344.25%
Revenue beat(8)6
Avg Revenue beat(8)90.61%
Revenue beat(12)6
Avg Revenue beat(12)49.19%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)24.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.29
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 0.63
EV/EBITDA N/A
EPS(TTM)-0.74
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.23
BVpS1.54
TBVpS1.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.79%
ROE -62.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-15.59%
ROA(5y)-38.9%
ROE(3y)-650.17%
ROE(5y)-521.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 3.13
Altman-Z -5.7
F-Score2
WACC11.22%
ROIC/WACCN/A
Cap/Depr(3y)103.18%
Cap/Depr(5y)61.91%
Cap/Sales(3y)3.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-155.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-143.66%
EPS Next 2Y-46.26%
EPS Next 3Y-11.24%
EPS Next 5Y-34.73%
Revenue 1Y (TTM)-93.7%
Revenue growth 3YN/A
Revenue growth 5Y251.82%
Sales Q2Q%-62.52%
Revenue Next Year-90.43%
Revenue Next 2Y-33.28%
Revenue Next 3Y-2%
Revenue Next 5Y-16.26%
EBIT growth 1Y-171.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.57%
OCF growth 3YN/A
OCF growth 5YN/A